Cardiol Therapeutics Inc Maintains Strong Buy Rating

First Berlin Equity Research has upheld its buy rating on Cardiol Therapeutics Inc, targeting a stable price of USD 7.50. Analyst Christian Orquera's analysis follows Cardiol's announcement of the Phase II MAvERIC trial data publication in the Journal of the American Heart Association. The findings corroborate previous reports on efficacy and safety in the treatment of recurrent pericarditis. Key insights include a five-day median time to pain relief, an 84% reduction in pericarditis episodes per year, and CRP normalization in 80% of patients.

The peer-reviewed publication lends independent validation to Cardiol's Phase II data, offering additional clinical context. As the Phase III MAVERIC enrolment is set to conclude in Q3 2026, results are anticipated by Q1 2027. While the publication does not introduce new efficacy data, it underpins the robust potential seen in Cardiol’s ongoing research efforts, reinforcing investor confidence amid continued developments in recurrent pericarditis treatments.